University of California

University of Pennsylvania

Other

Harvard College

Aduro Biotech Inc.

Daniel A Portnoy

Anat A Herskovits

Gregory Crimmins

Richard Lane Calendar

Peter M Lauer

Fred R Frankel

Darren E Higgins

Joshua J Woodward

Thomas W Dubensky, Jr

Yvonne Paterson

David N Cook

Sarah Stanley

William S Luckett, Jr

Mary O'Riordan

Chris Rae

Ian Glomski

Joel A Swanson

Erik Van Dis

Juliana Durack

Kyung-Dall Lee

Kimberly Sogi

Thomas P Burke

Jonathan L Portman

Thomas W Dubensky

William S Luckett

A vaccine against() formulated for intranasal administration, comprises a first vaccine component comprising one or more() or() antigens, and a second vaccine component comprising a Stimulator of Interferon Genes (STING) activator.

Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis

General secretory pathway (GSP) mutantbacteria are provided. Aspects of the bacteria include the presence of a GSP mutation, e.g., a SecY and/or SecA mutation. Also provided are methods of making and using thebacteria comprising a GSP mutation as vectors and vaccines expressing a heterologous nucleic acid.

General secretory pathway (GSP) mutant listeria SPP., and methods for making and using the same

Methods of assessing expression of a PrfA mediated expression construct in a Listerial host cell are provided. Aspects of the methods include maintaining a Listerial host cell that includes a PrfA mediated expression construct in a defined medium containing a reducing agent and evaluating expression of a product from the expression construct to assess expression of the PrfA mediated expression construct. Also provided are methods of producing and using a Listerial vaccine, as well as defined media for use in such methods.

Methods and compositions for modulating PrfA mediated virulence gene activation inspp

Mutantbacteria that modulate interferon-&#x3b2; production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.

Interferon-&#x3b2; production modulatingstrains and methods for using same

Methods of modulating type-I interferon production in a cell are provided. Aspects of the methods include modulating cytosolic cyclic di-adenosine monophosphate (c-di-AMP) activity in the cell in a manner sufficient to modulate type-I interferon production in the cell. Additional aspects of the invention include c-di-AMP activity modulatory compositions, e.g., c-di-AMP, mutantbacteria, cyclase and/or phosphodiesterase nucleic acid or protein compositions, etc. The subject methods and compositions find use in a variety of applications, including therapeutic applications.

Cyclic di-AMP induction of type I interferon

[object Object]

Site-specificintegration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source 0 of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study ofspecies and the preparation ofvaccines.

Interferon-&#x3b2; production modulating listeria strains and methods for using same

Mutantbacteria that modulate interferon-B production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.

Site-specificintegration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study ofspecies and the preparation ofvaccines.

Methods of eliciting or boosting a cellular immune response

Growing community of inventors

Albany, CA, United States of America

Daniel A Portnoy